pramipexole accord, inn-pramipexole · pramipexole accord is presented as tablets containing...
TRANSCRIPT
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 8545 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.
London, 21 July 2011 EMA/816841/2011 Committee for Medicinal Products for Human Use (CHMP)
Assessment report Pramipexole Accord
International nonproprietary name: pramipexole
Procedure No.: EMEA/H/C/2291
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
Table of contents
1. ............................................ 5 Background information on the procedure1.1. Submission of the dossier.................................................................................... 5 1.2. Manufacturers ................................................................................................... 6 1.3. Steps taken for the assessment of the product ....................................................... 7
2. .............................................................................. 8 Scientific discussion2.1. .................................................................................................... 8 Introduction2.2. ................................................................................................ 9 Quality aspects2.2.1. ............................................................................................... 9 Introduction2.2.2. ......................................................................................... 9 Active Substance2.2.3. .......................................................................... 11 Finished Medicinal Product2.2.4. ....................................... 12 Discussion on chemical and pharmaceutical aspects2.2.5. ................. 13 Conclusions on the chemical, pharmaceutical and biological aspects2.3. ...................................................................................... 13 Non- Clinical aspects2.3.1. Introduction.............................................................................................. 13 2.3.2. .................................................... 13 Ecotoxicity/environmental risk assessment2.3.3. Conclusion on the non-clinical aspects .......................................................... 14 2.4. .............................................................................................. 14 Clinical Aspects2.4.1. .............................................................................................. 14 Introduction2.4.2. ....................................................................................... 15 Pharmacokinetics2.4.3. ..................................................................................... 19 Pharmacodynamics2.4.4. .......................................................................................... 19 Additional data2.4.5. .......................................................................... 19 Post marketing experience2.4.6. ...................................................................... 19 Discussion on Clinical aspects2.4.7. ..................................................................... 19 Conclusions on clinical aspects2.5. ......................................................................................... 19 Pharmacovigilance2.6. ........................................................................................... 20 User consultation
3. ........................................................................... 20 Benefit-Risk Balance
4. ................................................................................. 20 Recommendation
Pramipexole Accord Assessment report EMA/816841/2011 Page 2/21
Pramipexole Accord Assessment report EMA/816841/2011
Page 3/21
List of Abbreviations
alu – aluminium
ASMF – Active Substance Master File
AUC0-t - area under the plasma concentration versus time curve from time zero to the last measurable
concentration
AUC0-∞ - area under the plasma concentration versus time curve
BE – Bioequivalence
BMI - Body Mass Index
CHMP - Committee for Medicinal Products for Human Use
Cmax - Maximum measured plasma concentration
13C-NMR – Carbon-13 Nuclear Magnetic Resonance
DA – Dopamine
EDTA - Ethylenediaminetetraacetic acid
EMA – European Medicines Agency
ERA - Environmental Risk Assessment
FT-IR – Fourier Transform InfraRed
GC – Gas Chromatography
GCP – Good Clinical Practice
1H-NMR – Proton (also Hydrogen-1) Nuclear Magnetic Resonance
HPLC – High Performance Liquid Chromatography
ICH – International Conference on Harmonisation
LOD - Limit of detection
LOQ - Limit of quantitation
MAH – Marketing Authorisation Holder
mg – milligram
MS – Mass Spectroscopy
Ph Eur - European Pharmacopoeia
PK - Pharmacokinetics
pKa – Acid dissociation constant (also acidity constant)
PD - Parkinson's disease
PSUR – Periodic Safety Update Report
RH – Relative Humidity
Pramipexole Accord Assessment report EMA/816841/2011
Page 4/21
RLS – Restless Legs Syndrome
RMP – Risk Management Plan
SmPC – Summary of Product Characteristics
t1/2 - elimination or terminal half-life
Tmax - time of maximum measured plasma concentration
UV – Ultraviolet
Pramipexole Accord Assessment report EMA/816841/2011
Page 5/21
1. Background information on the procedure
1.1. Submission of the dossier
The applicant Accord Healthcare Ltd submitted on 1 November 2010 an application for Marketing
Authorisation to the European Medicines Agency (EMA) for Pramipexole Accord 0.088 mg, 0.18 mg,
0.35 mg, 0.7 mg and 1.1 mg tablets, through the centralised procedure under Article 3 (3) of
Regulation (EC) No. 726/2004 – ‘Generic of a Centrally authorised product’. The eligibility to the
centralised procedure was agreed upon by the EMA/CHMP on 18 February 2010.
The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive
2001/83/EC and refers to a reference product for which a Marketing Authorisation is or has been
granted in the Union on the basis of a complete dossier in accordance with Article 8(3) of Directive
2001/83/EC.
The applicant applied for the following indication:
Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic
Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of
the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and
fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).
Pramipexole Accord is indicated in adults for symptomatic treatment of moderate to severe idiopathic
Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt).
The legal basis for this application refers to the Article 10(1) of Directive 2001/83/EC.
The application submitted is composed of administrative information, complete quality data and a
bioequivalence study with the reference medicinal product Mirapexin instead of non-clinical and clinical
data.
The chosen reference product is:
■ Medicinal product which is or has been authorised in accordance with Community provisions in
accordance with Community provisions in force for not less than 6/10 years in the EEA:
Product name, strength, pharmaceutical form: Mirapexin 0.088 mg, 0.18 mg, 0.35 mg,
0.7 mg, 1.1 mg tablets
Marketing authorisation holder: Boehringer Ingelheim International GmbH
Date of authorisation: 23-02-1998
Marketing authorisation granted by:
Community
Community Marketing authorisation number: EU/1/97/051/001-012
■ Medicinal product authorised in the Community/Members State where the application is made or
European reference medicinal product:
Product name, strength, pharmaceutical form: Mirapexin 0.088 mg, 0.18 mg, 0.35 mg,
0.7 mg, 1.1 mg tablets
Marketing authorisation holder: Boehringer Ingelheim International GmbH
Date of authorisation: 23-02-1998
Marketing authorisation granted by:
Pramipexole Accord Assessment report EMA/816841/2011
Page 6/21
Community
Community Marketing authorisation number: EU/1/97/051/001-012
■ Medicinal product which is or has been authorised in accordance with Community provisions in force
and to which bioequivalence has been demonstrated by appropriate bioavailability studies:
Product name, strength, pharmaceutical form: Mirapexin 0.18 mg tablets
Marketing authorisation holder: Boehringer Ingelheim International GmbH
Date of authorisation: 23-02-1998
Marketing authorisation granted by:
Community
Community Marketing authorisation numbers: EU/1/97/051/003-004
Bioavailability study number: 245-07
Scientific Advice
The applicant did not seek scientific advice at the CHMP.
Licensing status
The product was not licensed in any country at the time of submission of the application.
1.2. Manufacturers
Manufacturer responsible for batch release
Accord Healthcare Ltd.
Sage House
319 Pinner road
North Harrow, Middx HA1 4HF
United Kingdom
Pramipexole Accord Assessment report EMA/816841/2011
Page 7/21
applicant. The final consolidated List of Questions was sent to the applicant on
submitted the responses to the CHMP consolidated List of Questions on
rt on the applicant’s responses to the List of
the CHMP agreed on a list of outstanding issues to
ort on the applicant’s responses to the outstanding
a positive opinion for granting a Marketing
Authorisation to Pramipexole Accord on 21 July 2011.
1.3. Steps taken for the assessment of the product
The Rapporteur appointed by the CHMP was Eva Skovlund
The application was received by the EMA on 1 November 2010.
The procedure started on 17 November 2010.
The Rapporteur's first Assessment Report was circulated to all CHMP members on 4 February 2011.
During the meeting on 14-17 March 2011, the CHMP agreed on the consolidated List of Questions
to be sent to the
18 March 2011.
The applicant
21 April 2011.
The Rapporteur circulated the Assessment Repo
Questions to all CHMP members on 1 June 2011.
During the CHMP meeting on 20-23 June 2011,
be addressed in writing by the applicant.
The applicant submitted the responses to the CHMP list of outstanding issues on 27 June 2011.
The Rapporteur circulated the Assessment Rep
issues to all CHMP members on 7 July 2011.
During the meeting on 18-21 July 2011, the CHMP, in the light of the overall data submitted and
the scientific discussion within the Committee, issued
Pramipexole Accord Assessment report EMA/816841/2011
Page 8/21
2. Scientific discussion
2.1. Introduction
Pramipexole Accord 0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg, 1.1 mg tablets is a generic medicinal
product containing pramipexole, in form of the dihydrochloride monohydrate salt, as the active
substance. Pramipexole is administered orally.
Pramipexole is a synthetic amino-benzothiazole derivative. It has been shown to be a selective and
specific full DA receptor agonist with high affinity and selectivity for the DA D2 receptor subfamily, and
particularly the D3 receptor subtype. Pramipexole is a non-ergot dopamine agonist with actions similar
to those of bromocriptine. It is used in the management of Parkinson’s disease, alone or as an adjunct
to levodopa therapy in more advanced stages of the disease. Pramipexole is also indicated in adults for
symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to
0.54 mg of base (0.75 mg of salt).
The efficacy and safety of pramipexole has been demonstrated in randomised, placebo-controlled and
comparative trials. A summary of these studies may be found in the EPAR for Mirapexin.
The indication of Pramipexole Accord is the same as authorised for the reference medicinal product
Mirapexin. Mirapexin is indicated in adults for treatment of the signs and symptoms of idiopathic
Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of
the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and
fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations). Mirapexin is also
indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs
Syndrome in doses up to 0.54 mg of base (0.75 mg of salt).
Parkinson's disease (PD) is a neurodegenerative disorder characterised by bradykinesia, rigidity,
postural imbalance and tremor. The incidence of PD increases with age and on average, 2 to 3 % of
the population in the western world will develop PD. The cause of the disease is still unknown. PD
develops due to loss of neuronal functions within the basal ganglia and the substantia nigra of the
brain. More specifically, there is a marked deficiency in the nigrostriatal dopamine (DA) system due to
degeneration of nigral DA neurons. Thus, restoration of the dopaminergic transmission forms the
central strategy for the treatment of PD.
Restless Legs Syndrome (RLS) is a neurological sensory-motor disorder characterised by four essential
diagnostic criteria defined by the International Restless Legs Syndrome Study Group (IRLSSG) in 1995
and updated in 2003, with an estimated prevalence in the general population of 2.5% to 15%.
Dopamine agonists, including pramipexole, were regarded as first line treatment in ‘Principles and
Practice of Sleep Medicine’.
Mirapexin was authorised through the centralised procedure and therefore the qualitative and
quantitative composition of the active substance [pramipexole in form of the dihydrochloride
monohydrate salt] and the excipients [mannitol, maize starch, anhydrous colloidal silica, povidone,
magnesium stearate] is identical in all Member States. The formulation of Pramipexole Accord tablets
differs namely by the inclusion of microcrystalline cellulose which is not present in the reference
medicinal product.
The bioequivalence has been studied only with the 0.18 mg strength and for other strengths a
biowaiver was claimed.
2.2. Quality aspects
2.2.1. Introduction
Pramipexole Accord is presented as tablets containing pramipexole, in form of the dihydrochloride
monohydrate salt, as the active substance. Tablets contain 0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg or
1.1 mg of pramipexole which is an equivalent of respectively 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg and
1.5 mg of the salt.
The tablets are white to off-white, round, flat faced, bevel edged and differentiated by presence of a
breakline and appropriate bossing:
0.088 mg tablets: inscription ‘I1’ on one side and are plain on the other side
0.18 mg tablets: inscription ‘I’ and ‘2’ on either side of the breakline on one side and breakline on
the other side
0.35 mg tablets: inscription ‘I’ and ‘3’ on either side of the breakline on one side and breakline on
the other side
0.7 mg tablets: inscription ‘I’ and ‘4’ on either side of the breakline on one side and breakline on
the other side
1.1 mg tablets: inscription ‘I’ and ‘5’ on either side of the breakline on one side and breakline on
the other side
Excipients used in the preparation of Pramipexole Accord tablets are well known excipients such as
mannitol, maize starch, anhydrous colloidal silica, povidone, magnesium stearate and microcrystalline
cellulose.
Pramipexole Accord tablets are packed in aluminium (alu/alu) blisters.
2.2.2. Active Substance
Pramipexole dihydrochloride monohydrate, the active substance, is chemically designated as (6S)-6-N-
propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride monohydrate, and has the
following structure:
Pramipexole dihydrochloride monohydrate is a white or almost white crystalline powder. It is freely
soluble in water, soluble in methanol, slightly soluble in ethanol (96%) and practically insoluble in
methylene chloride. Its pKa is 7.2 and pH is 2.8 to 3.4. The molecule has one chiral center and exhibits
isomerism. In the manufacture of Pramipexole Accord tables, the same as for the reference medicinal
product, the S-enantiomer is used.
Manufacture
Information about manufacturing process has been provided using the Active Substance Master File
(ASMF) procedure. The active substance is synthesised in a two step synthesis followed by the salt
formation and purification step. Detailed description of the manufacturing process was provided.
Pramipexole Accord Assessment report EMA/816841/2011
Page 9/21
Pramipexole Accord Assessment report EMA/816841/2011
Page 10/21
Critical parameters and accompanying in-process controls, to ensure quality of the final compound,
have been defined and are controlled.
Confirmation of the chemical structure of pramipexole dihydrochloride monohydrate was provided by
elemental analysis (confirmation of the determined elementary composition), spectroscopic methods as
UV, FT-IR, 1H-NMR, 13C-NMR and MS (mass spectra). Also the physicochemical characteristics such us
polymorphism, solubility, pKa and pH have been investigated. Polymorphism was studied using the
X-ray diffraction.
Pramipexole dihydrochloride monohydrate was analyzed using the Ph Eur HPLC method to identify all
potential impurities. Impurities have been well characterised in relation to their origin and potential
carry-over into the final drug substance. Chemical names, structure, limit of detection (LOD) and limit
of quantitation (LOQ) along with their limits in the release specifications have been described. Other
impurities which were observed at minor concentrations are also controlled at a level of 0.10% under
Maximum Single Unknown Impurities and Total Impurities at a level of 0.50%. As the below mentioned
impurities are specified in the Ph Eur monograph, the structural elucidation for the same has not been
provided.
Specification
The active substance specification includes tests for appearance, solubility, appearance of solution,
identification (IR), specific optical rotation, presence of chlorides, pH, related substances (HPLC),
enantiomeric purity (HPLC), heavy metals, water content, sulphated ash, assay (potentiometric
titration), bioburden, residual solvents (GC), HCl content and particle size distribution (laser
diffraction). The specification generally complies with the Ph Eur monograph for pramipexole with
additional in-house tests for which suitable validation data are provided.
A detailed description for all analytical methods was provided. Most of the methods are Ph Eur apart
from particle size, HCl content and residual solvents. Full method validation data was provided for the
non compendial (in-house) analytical methods.
In general analytical methods proposed are suitable to control the quality of the drug substance.
Data on four batches of the active substance, used in the manufacture of the product used for
validation, bioequivalence (BE) and stability study have been presented. Results for all these batches
were provided by both the active substance and the finished product manufacturers. In addition results
for three recently manufactured batches were provided.
Certificates of analyses for the active substance were provided and all batch analysis results comply
with the specifications and show a good uniformity from batch to batch.
Stability
Stability studies were performed for the first three validation batches in accordance with the ICH
requirements under the following conditions: 40°C ± 2°C/75 ± 5% RH (accelerated),
30 ± 2°C/65% ± 5% RH (intermediate) and 25 ± 2°C/60% ± 5% RH (long term - real time). Data
obtained cover period of 5 years at long-term conditions and 6 months at accelerated conditions.
Forced degradation studies showed that pramipexole dihydrochloride monohydrate is stable under
exposure to elevated temperatures (heat), humidity (including in the dissolved state) and light. The
results were also within specifications after exposure to acid or alkaline conditions. Under oxidative
conditions an unknown impurity was observed.
Pramipexole Accord Assessment report EMA/816841/2011
Page 11/21
Results obtained from the stability studies demonstrated adequate stability of the active substance and
confirmed the proposed re-test period.
2.2.3. Finished Medicinal Product
Pharmaceutical Development
The aim of the pharmaceutical development was to obtain immediate release tablets, containing
quantitatively and qualitatively the same active substance as the reference medicinal product, and to
be bioequivalent.
Similarity with Mirapexin tablets was addressed by way of composition comparisons, dissolution studies,
solubility studies and comparative impurity profiles.
Compositions of Pramipexole Accord tablets and the reference medicinal product are similar. The
formulation of Pramipexole Accord tablets contain the same excipients as Mirapexin, and differ only by
the presence of microcrystalline cellulose which is not used in the reference medicinal product.
Similarity between Pramipexole Accord and the reference product was also shown by dissolution
testing. Comparative dissolution profiles of Pramipexole Accord 0.18 mg tablets and reference product
Mirapexin 0.18 mg tablets, and Pramipexole Accord 0.18 mg tablets and other strengths of
Pramipexole Accord tablets, in three different media: 0,1 M HCl, acetate buffer pH 4,5 and phosphate
buffer pH 6,8 have been conducted. The dissolution profiles of the test product and the reference
product were considered similar in all three media.
An impurity comparison of Pramipexole Accord and the reference product was undertaken. Results
showed no degradation to occur as a result of the manufacturing process as the impurity profile for the
generic product was similar to that of the product.
The application concerns five strengths however the bioequivalence was demonstrated between
Pramipexole Accord 0.18 mg tablets and Mirapexin 0.18 mg tablets, and a biowaiver for the 0.088 mg,
0.35 mg, 0.7 mg and 1.1 mg strengths was claimed. The biowaiver could be applied since:
other strengths are manufactured by the same manufacturer and process,
the drug input has been shown to be linear over the therapeutic dose range,
the qualitative composition of the strengths is the same; the amount of the active substance is
less than 5 % of the tablet weight and amounts of different excipients are the same for all the
concerned strengths and only the amount of active substance is changed.
the ratio between amounts of active substance and excipients is the same,
dissolution profiles of the additional strengths and the strength used in the bioequivalence study
were similar under identical conditions
The reference product is presented as uncoated tablets therefore Pramipexole Accord was also
developed as uncoated tablets.
Different formulations were prepared and studied during the development program. A formulation
optimisation study was performed regarding the effects of the concentration of excipients. The
selection of excipients was based not only on the reference product but also on the results from
laboratory scale formulations. The final formulation was chosen based on the results from these
studies.
Different technological processes such as direct tabletting and wet granulation were tested during the
development. Direct compression was selected as the final manufacturing process.
Pramipexole Accord Assessment report EMA/816841/2011
Page 12/21
Adventitious agents
None of the excipients used in the drug product are of animal origin. Magnesium stearate used in the
formulation is of vegetal origin.
Manufacture of the product
The proposed manufacturing process is dry, direct-compression. This standard manufacturing process
has been sufficiently characterised and includes weighing, sieving, mixing by co-sifting procedure and
compressing as steps during manufacture. A flow diagram and detailed description of the
manufacturing process have been provided. The critical steps and in-process controls have been
identified. Process validation has been carried out on three consecutive batches for all strengths of
Pramipexole Accord. The batch analysis results show that the medicinal product can be manufactured
reproducibly according the agreed finished product specifications.
Product Specification
The product specification is standard for tablets and contains tests with suitable limits for appearance
(description), average weight of tablets, identification (HPLC and UV), disintegration time, friability,
resistance to crushing, water content by loss on drying, dissolution, uniformity of dosage units (by
content uniformity), related substances (HPLC), assay (HPLC), subdivision of tablets and microbial
limits.
Full details of all analytical methods have been provided. All non pharmacopoeial methods have been
satisfactory validated. The HPLC methods used for assay, dissolution, content uniformity and related
substances have been validated in accordance with ICH requirements. As part of method validation,
stress studies (UV light, heat, water/acid/base hydrolysis and oxidation) were performed to provide an
indication of the stability-indicating properties and specificity of the HPLC method.
Batch analysis data was provided on three production scale batches of each strength. Batches met the
proposed specification limits. Results showed that tablets can be manufactured reproducibly according
to the finished product specifications.
Stability of the product
Stability studies were carried out under ICH conditions of 25ºC/60% RH (long term), 30ºC/65% RH
(intermediate) and 40ºC/75% RH (accelerated) on three production scale batches each of Pramipexole
Accord tablets.
Based on the stability data the proposed shelf-life and storage conditions as defined in the SmPC are
acceptable.
In summary the stability data provided support the proposed shelf-life and storage conditions.
2.2.4. Discussion on chemical and pharmaceutical aspects
Information about the active substance, pramipexole dihydrochloride monohydrate, has been provided
using the Active Substance Master File Procedure. The chemical-pharmaceutical documentation was of
acceptable quality.
The active substance has been satisfactorily characterized and the synthesis is well controlled.
Pramipexole dihydrochloride monohydrate is highly soluble and highly permeable, therefore was
classified as BCS class 1 active substance. Known and potential impurities have been satisfactorily
Pramipexole Accord Assessment report EMA/816841/2011
Page 13/21
addressed. The control tests and specifications for the active substance are in line with the ICH and
Ph Eur and are considered satisfactory. A retest period was supported by satisfactory stability studies
that show that the active substance is stable in solid form.
The finished product is an immediate release tablet containing 0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg or
1.1 mg of pramipexole in form of the dihydrochloride monohydrate salt. The composition of the
finished product has been described, and all excipients have been fully characterised.
The applicant has demonstrated that Pramipexole Accord is bioequivalent to the reference product
Mirapexin. The development pharmaceutics has been satisfactorily described and the formulation is
considered satisfactorily justified. The method of manufacture is considered standard and has been
satisfactorily described. Process validation has been carried out on three consecutive batches for all
strengths of Pramipexole Accord. The batch analysis results show that the product can be
manufactured reproducibly according the agreed finished product specifications.
The scope of the finished product specification complies with ICH Q6A and the Ph Eur requirements for
tablets, limits comply with regulatory requirements and are in line with batch data. The analytical
methods and validation data are satisfactory.
The stability program is considered satisfactory. The results generated during the stability studies
support the proposed shelf life and storage conditions as defined in the SmPC.
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
Information on development, manufacture and control of the active substance and the finished product
has been presented in a satisfactory manner. The results of tests carried out indicate that
physicochemical and biological aspects relevant to the uniform clinical performance of the product have
been investigated and are controlled in a satisfactory way. The quality of this product is considered to
be acceptable when used in accordance with the conditions defined in the SmPC.
2.3. Non- Clinical aspects
2.3.1. Introduction
A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided,
which is based on up-to-date and adequate scientific literature. The overview justifies why there is no
need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology data. The
non-clinical aspects of the SmPC are in line with the SmPC of the reference product.
2.3.2. Ecotoxicity/environmental risk assessment
No Environmental Risk Assessment (ERA) was submitted. This was justified by the applicant as the
introduction of Pramipexole Accord manufactured by Accord Healthcare Limited is considered unlikely
to result in any significant increase in the combined sales volumes for all pramipexole containing
products and the exposure of the environment to the active substance. Thus, the ERA is expected to
be similar and not increased.
Pramipexole Accord Assessment report EMA/816841/2011
Page 14/21
2.3.3. Conclusion on the non-clinical aspects
There is no need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology
data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. The
CHMP agreed that no further non-clinical studies are required.
2.4. Clinical Aspects
2.4.1. Introduction
This is an application for tablets containing pramipexole dihydrochloride monohydrate. To support the
marketing authorisation application the applicant conducted one bioequivalence study with cross-over
design under fasting conditions. This study was the pivotal study for the assessment.
No formal scientific advice by the CHMP was given for this medicinal product. For the clinical
assessment Guideline on the Investigation of Bioequivalence CPMP/EWP/QWP/1401/98 Rev.1 in its
current version is of particular relevance.
GCP
The Clinical trials were performed in accordance with GCP as claimed by the applicant
The applicant has provided a statement to the effect that clinical trials conducted outside the
community were carried out in accordance with the ethical standards of Directive 2001/20/EC.
Exemption
This application concerns 5 strengths of pramipexole dihydrochloride monohydrate; 0.125 mg
(=0.088 mg pramipexole), 0.25 mg (=0.18 mg pramipexole), 0.5 mg (=0.35 mg pramipexole),
1.0 mg (=0.7 mg pramipexole) and 1.5 mg (=1.1 mg pramipexole) but bioequivalence has been
studied with the 0.25 mg strength only. The applicant has applied for a biowaiver for the tablet
strengths of 0.125 mg, 0.5 mg, 1.0 mg and 1.5 mg.
According to the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98
Rev. 1/Corr**), there are general biowaiver criteria that should be fulfilled. For the current application,
all of the conditions of the requirements in the Bioequivalence guideline for a biowaiver are considered
fulfilled for all strengths. In conclusion, the CHMP considered a biowaiver for the additional strengths
acceptable.
Clinical studies
To support the application, the applicant has submitted one bioequivalence study performed with the
0.25 mg (=0.18 mg pramipexole base) strength. Since this is a generic application, no further clinical
studies are required and the applicant provides none.
Pramipexole Accord Assessment report EMA/816841/2011
Page 15/21
2.4.2. Pharmacokinetics
Methods
Study design
Project no. 245-07 was an open-label, balanced, randomised, two-treatment, two-period, two-
sequence, single oral dose, crossover bioequivalence study in healthy male subjects under fasting
conditions.
Either a single dose of 0.25 mg (0.18 mg pramipexole base) of Pramipexole dihydrochloride tablets or
Mirapexin 0.18 mg tablets was administered to each subject with 240 ml of water following an
overnight fast of at least 10 hours. Dinner was served approximately 10 hours before dosing. Four
hours after dosing snacks and meals were provided to the subjects at appropriate times.
Blood sampling was performed pre-dose and at 0.5, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.50, 2.75, 3, 3.5, 4,
5, 6, 8, 10, 12, 16, 20, 24, 48 and 72 hours following the drug administration in each period. The wash
out period was 7 days.
The study was performed at Lambda Therapeutic Research Ltd, Navi Mumbai, Maharashtra, India. The
bioanalysis facility was located in India.A statement of GCP compliance from the study centre was
submitted.
Test and reference products
Pramipexole dihydrochloride 0.25 mg tablets (0.18 mg pramipexole base) manufactured by Intas
Pharmaceuticals Limited, India (Batch No. L01436, exp. date 01/2012) has been compared to
Mirapexin 0.18 mg tablets manufactured by Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
(Batch No: 905343, exp. date 06/2012).
Population studied
Healthy, non smoking, Indian, male, adult volunteers aged between 18-55 years (mean age 26 years),
having a Body Mass Index (BMI) between 18.5-24.9 kg/m2 (mean BMI 22 kg/m2) and having given
their voluntary written informed consent, were enrolled in the study. They did not have any significant
diseases or clinically significant abnormal findings in any of the screening procedures carried out.
Volunteers who complied with all the inclusion and none of the exclusion criteria were enrolled into the
study. No female subjects were included in the trial. According to the applicant, the subject population
for the bioequivalence study was selected with the aim to minimize variability and permit detection of
differences between pharmaceutical products, and therefore the study was performed with healthy
males only.
The subjects were not allowed to take any medicine within 14 days prior to dosing. Subjects had to
abstain from consumption of grapefruits or its products within a period of 48 hours prior to dosing. In
addition the subjects had to abstain from any xanthine containing food or beverages (like chocolate,
tea, coffee or cola drinks), tobacco and tobacco containing products for 24 hours prior to dosing and
throughout the stay in the clinical facility. Alcohol and alcoholic products, cigarettes and recreational
drugs were not allowed until the last PK sample was taken.
A total of 30 subjects were checked-in for the study. Of these, 28 subjects were randomised to
treatment. Two subjects were extra subjects and they were not dosed.
A total of 28 subjects were dosed in period I and 25 subjects completed the study.
Pramipexole Accord Assessment report EMA/816841/2011
Page 16/21
3 subjects did not report for period II check-in due to personal reasons. They were considered to be
discontinued from the study on their own accord. These subjects were therefore not included in the
efficacy analysis.
Protocol deviations:
Samples were not collected within ±02 minutes of scheduled time for 4 subjects in period I and for 2
subjects in period II (these two were also two of the four in period I). The deviation varied from 7 to
260 minutes. The time points concerned were at 48 hours (2 subjects) and at 72 hours (4 subjects).
The reason for the deviations was late arrival of the subjects. Actual time points were used for the
pharmacokinetic and statistical evaluations.
Ambulatory samples were not collected for 3 subjects (at time point 72 hours) in period I (one of these
subjects were later excluded from the study because he did not show up for period II) and for 1
subject (at time point 48 hours) in period II. The reason for these missing samples was that the
subjects did not show up. Missing samples were denoted as “M” in the statistical analysis.
One subject in period I did not refrain from drinking water till 2 hours after dosing. He was given ice
cubes to suck to treat his adverse event (nausea).
Two subjects in period I did not follow the posture restriction deviation (to be in sitting or ambulatory
posture for 3 hours post dose). They were allowed to lie down due to adverse events (nausea and
dizziness).
The CHMP considered that the choice of population was acceptable, and that the protocol deviations
most probably did not affect the study results.
Analytical methods
Plasma samples (containing K2EDTA as anticoagulant) obtained in the bioequivalence study were
analysed for pramipexole by a validated LC/MS/MS analytical method as per in house procedures.
Sample analysis was conducted at Lambda Therapeutic Research Ltd., India to determine the plasma
concentration of pramipexole in the study sample. The long-term freezer stability for pramipexole has
been established for 589 days at -65oC + 10oC and covers the study sample storage period of twenty
six (26) days.
A total of 1147 plasma samples were analysed. In total 25 samples (2.2%) were reanalysed due to the
following reasons: 11 were repeated due to unidentified processing error, 7 were repeated due to
significant variation in response of internal standard, 6 were repeated due to low calibration curve
standard was eliminated, 1 was repeated due to anomalous concentration.
Pharmacokinetic Variables
Primary Parameters:
• Maximum measured plasma concentration (Cmax)
• The area under the plasma concentration versus time curve from time zero to the last measurable concentration (AUC0-t)
• The area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞)
Secondary Parameters:
• Time of maximum measured plasma concentration (Tmax)
• First order rate constant associated with the terminal (log -linear) portion of the curve (λz)
Pramipexole Accord Assessment report EMA/816841/2011
Page 17/21
• The elimination or terminal half-life (t1/2)
• % of residual area (AUC_% Extrap_obs)
The pharmacokinetic parameters were calculated by non-compartmental model using WinNonlin
Professional Software Version-5.0.1 (Pharsight Corporation, USA).
Statistical comparison of the pharmacokinetic parameters of the two formulations was carried out
using PROC MIXED of SAS® Release 9.1.3 (SAS Institute Inc., USA) to assess the bioequivalence of
both the formulations.
The CHMP considered that the choice of the primary pharmacokinetic variables and non-compartmental
method was acceptable.
Statistical methods
Dataset for the estimation of pharmacokinetic parameters was prepared using WinNonlin Professional
Software (Version 5.0.1) for pramipexole. Estimation of pharmacokinetic parameters was also carried
out using the same software. Descriptive statistics of the pharmacokinetic parameters were calculated
and reported for pramipexole.
Statistical analysis was performed on the data obtained by assaying the pramipexole content in plasma
samples using SAS® Release 9.1.3 (SAS Institute Inc., USA). The comparison of the pharmacokinetic
parameters was carried out using PROC MIXED of SAS® Release 9.1.3 (SAS Institute Inc., USA).
Analysis of variance was carried out by employing PROC MIXED of SAS® Release 9.1.3 (SAS Institute
Inc., USA) for un-transformed and ln-transformed pharmacokinetic parameters Cmax, AUC0-t and
AUC0-∞ for pramipexole.
ANOVA model included Sequence, Formulation and Period as fixed effects and Subject (Sequence) as a
random effect. Sequence effect was tested using Subject (Sequence) as error term. An F-test was
performed to determine the statistical significance of the effects involved in the model at a significance
level of 5% (alpha=0.05). Two one-sided tests for bioequivalence and 90% confidence intervals for the
ratio of the least squares means between the test and reference formulations were calculated for
untransformed and ln-transformed data of Cmax, AUC0-t and AUC0-∞ for pramipexole. The power of test
to detect 20% difference between test and reference formulations was computed and reported for un-
transformed and ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ for pramipexole.
Ratio of least squares means of test and reference formulation was computed for untransformed and
ln-transformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ of pramipexole.
Ratio analysis was reported for un-transformed and ln-transformed pharmacokinetic parameters Cmax,
AUC0-t and AUC0-∞ for pramipexole.
To be considered bioequivalent, the 90% confidence intervals of Cmax, AUC0-t and AUC0-∞ had to fall
within an acceptance range of 80-125%.
The CHMP considered that the statistics had been adequately described and the methods were
considered acceptable.
Results
The pharmacokinetic parameters for the test and reference products are shown in Table 1.
Pramipexole Accord Assessment report EMA/816841/2011
Page 18/21
Table 1. Pharmacokinetic parameters (non-transformed values; arithmetic mean ± SD, tmax median, range)
Treatment AUC0-t
xg/ml/h
AUC0-∞
xg/ml/h
Cmax
xg/ml
tmax
h
T1/2
h
Test
5590.67±976.88
6257.81±1163.60
519.00±84.43 2.50 (1.00-5.00)
7.072±1.20
Reference
5627.68±915.05
6283.40±1057.73
525.88±94.41 2.25 (1.50-6.00)
7.031±0.84
*Ratio (90% CI)
99.4 (97.16-101.74)
99.5 (97.32-101.77)
98.9 (95.19-102.86)
- -
CV (%) 4.7 % 4.6 % 7.9 % - - AUC0-∞ area under the plasma concentration-time curve from time zero to infinity
AUC0-t area under the plasma concentration-time curve from time zero to t hours
Cmax maximum plasma concentration
Tmax time for maximum concentration
T1/2 half-life *ln-transformed values
The CHMP concluded that bioequivalence between the test and reference product has been
appropriately shown. The 90% confidence intervals for the ln-transformed Cmax, AUC0-t and AUC0-∞
were within the acceptance range of 80-125%. The randomization scheme was considered appropriate.
AUC0-t derived from the measurements was covering 80% or more of the AUC0-∞ for all the subjects
included, demonstrating that the 72 hours sampling time was sufficient to estimate the bioavailability
of pramipexole.
No pre-dose levels of pramipexole were detected in any subjects, showing that the wash-out period
was long enough to avoid any carry-over effects.
According to the applicant, formulation, sequence and period effects for ln-transformed data for Cmax
and AUC0-∞ were found to be statistically insignificant. For AUC0-t the formulation and sequence effects
for the ln-transformed data were also statistically insignificant, however the period effect was
statistically significant (p=0.0247). The MAH provided an acceptable explanation for this finding and
the issue was considered to be resolved.
For the sampling points 48 and 72 hours, all plasma samples for all subjects were below limit of
quantification. For one subject the plasma sample was below limit of quantification for the sample point
24 hours. No samples were above the limit of quantification.
Safety data
There were no deaths, serious or significant adverse events. Two subjects reported a total of two
adverse events during the course of the study. Both adverse events (nausea and dizziness) were
reported after receiving the reference product. They were considered possibly related to the
administered medicinal product, mild in nature and both resolved. No adverse events were reported for
the test product.
Upon conclusion of the clinical portion of the study, the results from all subjects, who completed post-
study procedures including laboratory tests and vital signs measurements confirmed the absence of
significant changes in the subjects' state of health.
Pramipexole Accord Assessment report EMA/816841/2011
Page 19/21
Conclusions
Based on the presented bioequivalence study Pramipexole Accord is considered bioequivalent with
Mirapexin.
The results of Study Project no. 245-07 with the 0.18 mg formulation can be extrapolated to the other
applied strengths (0.088 mg, 0.35 mg, 0.7 mg and 1.1 mg), according to conditions in Guideline on
the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 1/Corr**).
2.4.3. Pharmacodynamics
No new pharmacodynamic studies were presented and no such studies are required for this
application.
2.4.4. Additional data
Not applicable.
2.4.5. Post marketing experience
No post-marketing data are available. The medicinal product has not been marketed in any country.
2.4.6. Discussion on Clinical aspects
The CHMP assessment addressed pharmacokinetic data for a single bioequivalence study (Project no.
245-07). One single dose bioequivalence study is considered acceptable as the product is an
immediate release formulation. The CHMP considered the design of the study to be acceptable. The
sampling period of 72 hours is considered sufficient, and the wash-out period of 7 days is long enough
to avoid any carry-over effect to the second period. The CHMP considered the analytical method used
in the bioequivalence study to be acceptable. The study was conducted in line with GCP. The CHMP
considered that bioequivalence between the test and reference product has been appropriately shown.
The 90% confidence intervals for the ln-transformed Cmax, AUC0-t and AUC0-∞ were within the
acceptance range of 80-125%.
2.4.7. Conclusions on clinical aspects
Based on the presented bioequivalence study, Pramipexole Accord 0.18 mg tablet is considered
bioequivalent with Mirapexin 0.18 mg tablet.
2.5. Pharmacovigilance
Detailed description of the Pharmacovigilance system
The CHMP considered that the Pharmacovigilance system as described by the applicant fulfils the
legislative requirements.
Risk Management Plan
The CHMP did not require the applicant to submit a Risk Management Plan (RMP) because in general, it
is accepted that RMPs are not required for generic products unless a safety concern requiring additional
risk minimisation activities has been identified for the reference medicinal product. There is an RMP in
place for Mirapexin, but there are no additional risk minimisation activities implemented except routine
Pramipexole Accord Assessment report EMA/816841/2011
Page 20/21
activities in the form of information in the SmPC/PIL and labelling. The applicant has included in the
proposed SmPC the information specified in the RMP of the reference product. At the request of the
CHMP, the applicant has included also the changes resulting from variation application
EMEA/H/C/xxxx/WS/0041/G which concerned an update of section 4.8 and other sections of the SmPC
for the reference product. The CHMP considered the updated SmPC to be acceptable.
The CHMP, having considered the data submitted, was of the opinion that routine pharmacovigilance
was adequate to monitor the safety of the product.
2.6. User consultation
No full user consultation with target patient groups on the package leaflet has been performed on the
basis of a bridging report making reference to Mirapexin. The bridging report submitted by the
applicant has been found acceptable.
3. Benefit-Risk Balance
This application concerns a generic version of pramipexole dihydrochloride monohydrate tablets. The
reference product Mirapexin is indicated for the treatment of idiopathic Parkinson’s disease and for the
symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome. No nonclinical
studies have been provided for this generic application but an adequate summary of the available
nonclinical information for the active substance was presented and considered sufficient. From a
clinical perspective, this application does not contain new data on the pharmacokinetics and
pharmacodynamics as well as the efficacy and safety of the active substance; the applicant’s clinical
overview on these clinical aspects based on information from published literature was considered
sufficient.
The bioequivalence study forms the pivotal basis with an open-label, randomised, two-treatment, two-
period, two-sequence, single oral dose, crossover design. The study design was considered adequate
to evaluate the bioequivalence of this formulation and was in line with the respective EU requirements.
The choice of dose, sampling points, overall sampling times as well as wash-out period were adequate.
The analytical method was validated. Pharmacokinetic and statistical methods applied were adequate.
The test formulation of Pramipexole Accord met the protocol-defined criteria for bioequivalence when
compared with Mirapexin tablets. The point estimates and their 90% confidence intervals for the
parameters AUC0-t, AUC0- and Cmax were all contained within the protocol-defined acceptance range of
80.00 to 125.00%. Bioequivalence of the two formulations was demonstrated.
A benefit/risk ratio comparable to the reference product can therefore be concluded.
The CHMP, having considered the data submitted in the application and available on the chosen
reference medicinal product, is of the opinion that no additional risk minimisation activities are
required beyond those included in the product information.
4. Recommendation
Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus
that the benefit-risk balance of Pramipexole Accord in the treatment of Parkinson’s disease and
moderate to severe idiopathic Restless Legs Syndrome is favourable and therefore recommends the
granting of the marketing authorisation subject to the following conditions:
Pramipexole Accord Assessment report EMA/816841/2011
Page 21/21
Conditions or restrictions regarding supply and use
Medicinal product subject to medical prescription
Conditions and requirements of the Marketing Authorisation
Pharmacovigilance System
The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1 of the
marketing authorisation, is in place and functioning before and whilst the product is on the market.
Risk Management System
Not applicable
PSUR cycle
The PSUR cycle for the product will follow PSURs submission schedule for the reference medicinal product.
Conditions or restrictions with regard to the safe and effective use of the medicinal product
Not applicable.
Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States
Not applicable.